The landscape of interventional trials in Parkinson disease: A 10-year review of ClinicalTrials.gov between 2006 and 2016
Objective: To review the scope of interventional trials for Parkinson disease registered on clinicaltrials.gov in the past 10 years. Background: Parkinson disease (PD) is a broad chronic condition…Gait Asymmetry and Parkinson’s Disease
Objective: To evaluate gait asymmetry using velocity-dependent gait analysis and compare to UPDRS asymmetries. Background: Motor impairment, including gait impairment, in patients with Parkinson’s disease…Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)
Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…Effect of food on Opicapone pharmacokinetics and pharmacodynamics
Objective: To characterize the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of opicapone (OPC) after single and repeated doses. Background: OPC, a…Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease
Objective: To employ a combination of elemental concentrations in the cerebrospinal fluid (CSF) to identify a diagnostic biomarker profile differentiating patients with idiopathic Parkinson´s disease…Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease
Objective: We investigated whether dopamine transporter single-photon emission computed tomography (DAT-SPECT) binding correlates to non-motor symptoms in patients with Parkinson’s disease (PD). Background: DAT-SPECT binding…Dopamine transporter imaging predicts motor response to dopaminergic therapy for patients with advanced Parkinson’s disease: Possible role in patient selection for subthalamic deep brain stimulation.
Objective: To investigate the possible role of dopamine transporter (DAT) imaging in patient selection for subthalamic deep brain stimulation (STN-DBS) surgery, we retrospectively investigated the…Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease
Objective: To directly compare 18F-DOPA with a highly specific dopamine transporter radioligand 11C-PE2I, for the assessment of motor severity and rate of progression in Parkinson's…Neural correlates of minor hallucinations in Parkinson’s disease: A multimodal imaging study
Objective: To explore the neural correlates sub-serving isolated minor hallucinations in Parkinson's disease (PD) through a multimodal structural and functional neuroimaging approach based on grey matter…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 155
- Next Page »